HBY

Hybridon (HBY)

Hybridon

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:AMEX:HBY

1 2 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2005/09/12	22:12	PR Newswire (US)	Hybridon Changes Name to Idera Pharmaceuticals	AMEX:HBY	Hybridon
2005/09/08	23:33	PR Newswire (US)	Hybridon, Inc. to Present at ThinkEquity Growth Conference	AMEX:HBY	Hybridon
2005/06/21	22:00	PR Newswire (US)	Hybridon, Inc., to Participate in Innate Immunity Panel at the BIO 2005 Annual International Convention	AMEX:HBY	Hybridon
2005/06/17	23:05	PR Newswire (US)	Hybridon Announces the Appointment of Robert W. Karr, M.D. to its Board of Directors	AMEX:HBY	Hybridon
2005/06/01	15:00	PR Newswire (US)	Hybridon Announces Collaboration to Develop Immune Modulatory (IMO) Compounds for Asthma and Allergy	AMEX:HBY	Hybridon
2005/05/21	03:20	PR Newswire (US)	Hybridon Announces $5 Million Private Financing	AMEX:HBY	Hybridon
2005/05/16	22:55	PR Newswire (US)	Hybridon Presents Preclinical Data on Interferon-Alpha Induction by Toll-Like Receptor 9 Agonists	AMEX:HBY	Hybridon
2005/05/16	22:35	PR Newswire (US)	Hybridon Announces Oral Presentation of Results for Phase I Trial of IMOxine(R) at ASCO 2005	AMEX:HBY	Hybridon
2005/05/11	23:05	PR Newswire (US)	Hybridon Publishes Data on Novel Synthetic Agonists of Toll-Like Receptor 9	AMEX:HBY
2005/05/03	23:05	PR Newswire (US)	Hybridon, Inc. to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference	AMEX:HBY	Hybridon
2005/04/18	23:05	PR Newswire (US)	Hybridon Presents New Preclinical Antitumor Data at AACR Supporting its IMOxine Development Program	AMEX:HBY	Hybridon
2005/03/29	00:05	PR Newswire (US)	Hybridon Reports 2004 Financial Results	AMEX:HBY	Hybridon
2005/03/03	22:00	PR Newswire (US)	Hybridon's Toll-like Receptor 9 Agonist Enhances Antitumor Activity of Cetuximab in Preclinical Studies	AMEX:HBY
2005/02/22	22:01	PR Newswire (US)	Hybridon, Inc. to Present at BIO CEO and Investor Conference	AMEX:HBY
2004/11/22	22:00	PR Newswire (US)	Hybridon Provides Updated Interim Results for the Phase 1 Trial of IMOxine(TM)	AMEX:HBY	Hybridon
2004/11/15	22:00	PR Newswire (US)	Hybridon Announces Two Presentations at the American College of Allergy, Asthma, & Immunology Annual Meeting	AMEX:HBY	Hybridon
2004/11/02	22:00	PR Newswire (US)	Hybridon to Present at Two Upcoming Conferences	AMEX:HBY	Hybridon
2004/10/26	22:00	PR Newswire (US)	Hybridon Initiates Phase 2 Trial of Its Oncology Drug Candidate, IMOxine(TM)	AMEX:HBY	Hybridon
2004/10/25	22:01	PR Newswire (US)	Hybridon to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference	AMEX:HBY	Hybridon
2004/10/06	22:01	PR Newswire (US)	Hybridon Appoints Dr. Naveen N. Anand as Vice President, Corporate and Business Development	AMEX:HBY	Hybridon
2004/09/24	00:24	PR Newswire (US)	Hybridon Appoints Alison Taunton-Rigby to Board of Directors	AMEX:HBY	Hybridon
2004/09/14	21:01	PR Newswire (US)	The Immune Response Corporation Presents New Phase II Clinical Data Indicating That REMUNE(R) Induces a HIV-Specific Immune Resp	AMEX:HBY	Hybridon
2004/08/30	23:15	PR Newswire (US)	Hybridon Announces Closing of $5.1 Million Equity Private Placement; Appointment of Sudhir Agrawal, D.Phil. as Chief Executive O	AMEX:HBY	Hybridon
2004/08/04	07:15	PR Newswire (US)	Hybridon Licenses Key VEGF Patents to Alnylam for Treatment of Ocular Diseases with RNAi Therapeutics	AMEX:HBY	Hybridon
2004/07/28	00:00	PR Newswire (US)	The Immune Response Corporation Presents Data at the International Congress of Immunology on HIV Product Candidate IR103	AMEX:HBY	Hybridon
2004/07/22	22:00	PR Newswire (US)	Hybridon's Immunomodulatory Oligonucleotides Demonstrate Mucosal Immune Responses and Adjuvant Activity Following Oral Administr	AMEX:HBY	Hybridon
2004/07/15	21:00	PR Newswire (US)	The Immune Response Corporation Presents Data Demonstrating IR103 HIV-Specific Immunologic Activity at XV International AIDS Con	AMEX:HBY	Hybridon
2004/06/16	22:00	PR Newswire (US)	Hybridon Inc. to Present at the Third Annual Needham Biotechnology Conference	AMEX:HBY	Hybridon
2004/05/12	22:00	PR Newswire (US)	Hybridon Inc. to Present at the Rodman & Renshaw Techvest Global Healthcare Conference	AMEX:HBY	Hybridon
2004/05/10	22:02	PR Newswire (US)	Hybridon's Immunomodulatory Drug Candidate, IMOxine(TM), Produces Immune Response in Patients with Refractory Advanced Solid Tum	AMEX:HBY	Hybridon